Atherosclerosis and Lipoproteins |
From Pharmaceuticals Research Laboratories, Fujirebio Inc, Hachioji, Tokyo, Japan.
Correspondence to Jun Kusunoki, Pharmaceuticals Research Laboratories, Fujirebio Inc, 51 Komiya-cho, Hachioji, Tokyo 192-0031, Japan.
AbstractPostprandial
hyperlipidemia (PH) is recognized as a significant risk
factor for cardiovascular disease. The present
study, involving rats with streptozotocin (STZ)-induced diabetes, was
performed to establish a PH model and to examine the relation between
small intestinal acyl-coenzyme A:cholesterol
acyltransferase (ACAT) activity and serum lipid levels in the
postprandial state. The small intestinal ACAT activities in normal rats
during the experimental period were 4 to 5 pmol/mg protein per minute.
In contrast, in the diabetic rats, the ACAT activities were 2 to 3
times higher than activities seen in normal rats from 7 to 21 days
after the STZ injection in the absence of a high fat diet and
hyperplasia in the gut. In an oral fat-loading test that used diabetic
rats that had been injected with STZ (60 mg/kg)
intravenously 14 days previously, the postloading changes
in the serum concentrations of total cholesterol (TC) and
triglyceride (TG) were significantly greater in the
diabetic rats than in normal rats. Single oral administration of
(1s,2s)-2-[3-(2,2-dimethylpropyl)-3-nonylureido]cyclohexane-1-yl
3-[(4R)-N-(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propionate
(F-1394, 3 to 30 mg/kg), a potent ACAT inhibitor,
suppressed the postfat-loading elevation of serum TC levels in the
diabetic rats in a dose-dependent manner without affecting serum
glucose levels. Furthermore, the small intestinal ACAT activity, serum
TG levels, and lymphatic absorption of TC and TG in the rats that were
administered F-1394 (30 mg/kg) were reduced by
90%, 70%, 30%, and
15%, respectively. This is the first evidence that elevated ACAT
activity in the gut, unlike hyperplasia and hyperphagia, induces PH in
rats. Our results strongly suggest that F-1394 may be a potential
treatment for PH in humans.
Key Words: acyl coenzyme A:cholesterol acyltransferase streptozotocin-induced diabetic rats postprandial hyperlipidemia F-1394 fat-loading test
This article has been cited by other articles:
![]() |
M. Hori, M. Satoh, K. Furukawa, Y.-i. Sakamoto, H. Hakamata, Y. Komohara, M. Takeya, Y. Sasaki, A. Miyazaki, and S. Horiuchi Acyl-Coenzyme A:Cholesterol Acyltransferase-2 (ACAT-2) Is Responsible for Elevated Intestinal ACAT Activity in Diabetic Rats Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1689 - 1695. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kusunoki, D. K. Hansoty, K. Aragane, J. T. Fallon, J. J. Badimon, and E. A. Fisher Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice Circulation, May 29, 2001; 103(21): 2604 - 2609. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Aragane, K. Fujinami, K. Kojima, and J. Kusunoki ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits J. Lipid Res., April 1, 2001; 42(4): 480 - 488. [Abstract] [Full Text] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |